Topically applied novel TRPV1 receptor antagonist, ACD440 Gel, reduces evoked pain in healthy volunteers, a randomized, double‐blind, placebo‐controlled, crossover study

• Published in: European journal of pain Vol. 28; no. 10; pp. 1656 - 1673
• Main Authors: Segerdahl, M., Rother, M., Halldin, M. M., Popescu, T., Schaffler, K.
• Format: Journal Article
• Language: English
• Published: England 01.11.2024
• Subjects: Administration, Cutaneous; Administration, Topical; Adult; Analgesics - administration & dosage; Analgesics - pharmacokinetics; Analgesics - pharmacology; Cross-Over Studies; Double-Blind Method; Female; Gels; Healthy Volunteers; Humans; Laser-Evoked Potentials - drug effects; Male; Middle Aged; Pain - drug therapy; Pain Measurement; Skin - drug effects; TRPV Cation Channels - antagonists & inhibitors; Young Adult
• ISSN: 1090-3801; 1532-2149
• DOI: 10.1002/ejp.2299

Background The TRPV1 receptor is a key molecule in pain generation. Previous development of oral TRPV1‐antagonists was halted due to systemic heat insensitivity and body temperature alterations. The present Phase 1b study investigated the efficacy, safety and plasma exposure of a topically administe...